Effect of WSP, a Chinese Herbal Formula, on Th17/Treg Ratio and HBeAg Seroconversion in Telbivudine-Treated HBeAg-Positive Chronic Hepatitis B Patients with High Baseline ALT Levels (20–30 Times the ULN)

Table 2

Baseline data comparison between treatment and control groups.

Group	Treatment (n = 34)	Control (n = 34)	t/χ^2	P value
Age (yr)	41.26±7.81	43.17±8.20	0.983	0.329
Males (n, %)	25(73.5)	22 (64.7)	0.620	0.431
HBV DNA (log10 copies/mL)	7.18±1.22	7.16±1.27	0.066	0.947
Genotype (B /C/B+C)	17/16/1	19/13/2	0.757	0.686
ALT (U/L)	993.42±151.61	985.67±148.43	0.378	0.707
TBIL (μmol/L)	29.51±12.64	27.40±13.86	0.656	0.514
PTA (%)	78.51±9.98	81.84±16.07	1.026	0.308
Creatinine (μmol/L)	45.73± 22.37	41.03±26.94	0.783	0.437
Th17/Treg cells ratio	0.46±0.14	0.43±0.12	0.949	0.346

All values are expressed as mean ± SD or number (%). HBV, hepatitis B virus; ALT, alanine aminotransferase; TBIL, total bilirubin; PTA, prothrombin activity; Th, T helper cells; Treg, regulator T cells.